Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

<< Previous

Bullboard Posts

Next >>

Post by AUborealison Jan 15, 2021 4:32pm

278 Views

Post# 32308719

Every Type 1 sufferor should own this and

in 2-3 years will be able to pay for the treatment, their retirement, and the condo on a golf course, anywhere in the world.

It's only worth $100MM USD now, and the technology is good for more than just T1D.

Statistics

Some 1.6 million Americans are living with T1D, including about 200,000 youth (less than 20 years old) and more than 1 million adults (20 years old and older).1,5
64,000 people are diagnosed each year in the U.S.2
5 million people in the U.S. are expected to have T1D by 2050, including nearly 600,000 youth.3
Between 2001 and 2009, there was a 21 percent increase in the prevalence of T1D in people under age 20.3
In the U.S., there are $16 billion in T1D-associated healthcare expenditures and lost income annually.
Less than one-third of people with T1D in the U.S. are consistently achieving target blood-glucose control levels.6